Associate Director, Clinical Program Management Leader

Johnson & Johnson Innovative Medicine; Beerse; Hybride; EUR 96 000 - 165 000; Plein temps

Avantages offerts par ce poste

Annual bonus

Vacation days

Parental leave

Bereavement leave

Well-being reimbursement

Insurance plans

Résumé du poste

Johnson & Johnson Innovative Medicine in Beerse, Belgium, is seeking an Associate Director, Program Management Leader (PML) to translate the CDT strategy into an actionable Compound Development Plan and lead the cross-functional PMT in a hybrid setup.

You will apply PM methodologies, manage risk, and ensure program execution across early and late drug development phases, collaborating with global teams. Up to 20% travel may be required.

Qualifications

• Bachelor's degree in Life Science or related field is required.
• 8+ years in pharmaceutical/healthcare project management.
• Experience across early and late study phases (I–IV) is preferred.
• Clinical research operational knowledge is required.

Responsabilités

• Translate CDT strategy into a Compound Development Plan enabling program execution.
• Lead and manage the PMT across functions to establish and implement the program execution plan.
• Monitor scope, timelines and budget in collaboration with cross-functional partners.
• Develop, maintain and communicate cross-functional risk-management registers.
• Ensure the program stays on track financially and schedule-wise, driving issue mitigation.
• Up to 20% domestic and international travel may be required.

Connaissances

Leadership

Communication skills

Project Management

Analytical skills

Negotiation

Formation

Bachelor's degree in Life Science

Advanced degree (MS/PhD)

Outils

PM tools

PM methodologies

Description du poste

Johnson & Johnson Innovative Medicine in Beerse, Belgium, is seeking an Associate Director, Program Management Leader (PML) to translate the CDT strategy into an actionable Compound Development Plan and lead the cross-functional PMT in a hybrid setup.

You will apply PM methodologies, manage risk, and ensure program execution across early and late drug development phases, collaborating with global teams. Up to 20% travel may be required.